S&CO Inc. Cuts Stake in Johnson & Johnson $JNJ

S&CO Inc. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 158,763 shares of the company’s stock after selling 4,960 shares during the period. Johnson & Johnson comprises about 1.8% of S&CO Inc.’s investment portfolio, making the stock its 15th biggest position. S&CO Inc.’s holdings in Johnson & Johnson were worth $29,437,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new position in shares of Johnson & Johnson in the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. increased its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. Compass Financial Services Inc raised its holdings in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after buying an additional 198 shares during the last quarter. Finally, Signature Resources Capital Management LLC boosted its position in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after buying an additional 184 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.6%

Shares of NYSE:JNJ opened at $238.62 on Tuesday. The firm has a market capitalization of $574.90 billion, a P/E ratio of 21.59, a P/E/G ratio of 2.33 and a beta of 0.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50 day moving average price of $214.20 and a 200-day moving average price of $194.70. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $240.93.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting the consensus estimate of $2.46. The company had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Bank of America boosted their price objective on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday, January 22nd. Royal Bank Of Canada raised their target price on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, Wells Fargo & Company lifted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.